Celularity Inc.
Moat Score — Celularity Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Celularity's placental-tissue sourcing and processing platform and cell therapy pipeline (including PDA-001) represent real proprietary science, though none of its therapeutic candidates has reached full commercial approval. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | At a roughly $38 million market cap with declining revenue, Celularity has no scale or cost advantage versus larger, better-funded cell therapy and biobanking competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | A 51% year-over-year revenue decline indicates essentially no pricing power or demand resilience in current product lines. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Cell therapy and biobanking services carry no network effect between customers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Families who have already banked placental or cord tissue with Celularity are unlikely to move that stored material elsewhere, giving the BioBanking segment modest recurring-revenue stickiness, though this does not extend to the broader therapeutics business. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The cell therapy and biobanking markets include larger, more established competitors, and Celularity's small, financially strained scale provides no efficient-scale protection. |